During the past decade, Clinical Hospital Merkur conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinical Hospital Merkur" #1 sponsor was "Clinical Hospital Merkur" with 3 trials, followed by "Šarić, Jadranka Pavičić, M.D." with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Advanz Pharma" with 1 trials sponsored and "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 1 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinical Hospital Merkur" #1 collaborator was "Clinical Hospital Centre Zagreb" with 1 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 1 trials as a collaborator, "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Janssen Pharmaceuticals" with 1 trials as a collaborator and "Pharmacyclics LLC." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Clinical Hospital Merkur" are "Acute Myeloid Leukemia" (2 trials), "Arm Injuries" (2 trials), "Chronic Lymphocytic Leukemia" (2 trials), "Diffuse Large B-Cell Lymphoma" (2 trials) and "Acute Myeloid Leukemia (AML)" (1 trials). Many other conditions were trialed in "Clinical Hospital Merkur" in a lesser frequency.

Most popular intervention types in "Clinical Hospital Merkur" are "Drug" (15 trials), "Other" (2 trials), "Biological" (1 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Rituximab" (4 trials), "Bendamustine" (2 trials), "Idelalisib" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Clinical Hospital Merkur" are 23 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Clinical Hospital Merkur". undefined are not yet recruiting, 6 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Clinical Hospital Merkur, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Clinical Hospital Merkur, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".